ABSTRACT
INTRODUCTION
V oltage-gated Ca 2 + -selective channels play essential roles in the control of neurosecretion and muscle contraction. The channels have been categorized as L-, N-, P/Q-, R-, or T-type based on functional and pharmacological properties. Sequence similarity has identified three subfamilies Ca v 1, Ca v 2, and Ca v 3, where Ca v 1 and Ca v 3 correspond to L-and T-type, respectively. Ca v 2 encompasses N-, R-, and P/Q types. Each subtype contains a pore-forming a 1 -subunit accompanied by auxiliary subunits (e.g., a 2 d, b [1] [2] [3] [4] , and g) that modify gating, subcellular trafficking, and drug binding characteristics. 1 Development of drugs that act as calcium channel blockers has been successful for L-type channels in cardiovascular indications, for example, hypertension, heart failure, and atrial fibrillation. The success in this area has been due largely to state-dependent and usedependent characteristics of the drug-channel interaction such that the inhibitory effect is most pronounced at partially depolarized membrane potential, thus preserving normal function. 2 Another area of calcium channel drug development has focused on neurologic disorders, including pain and epilepsy. Cav2.2 (N-type) has been identified as a valid pain target that can be inhibited by the selective blocker ziconotide to relieve chronic pain. 3 However, recent development has centered on identifying state-dependent Ca v 2.2 inhibitors, which preferentially bind to channels in open or inactivated states that may improve the therapeutic window over relatively state-independent Ca v 2.2 inhibitors, such as ziconotide. 4 Antiepileptic calcium channel inhibitors are exemplified by ethosuximide, broadly selective blockers of T-type (Cav3.x) channels. 5 Another example is gabapentin, which inhibits Cav2.x trafficking through interaction with the a 2 d 1 auxiliary subunit and is approved for treatment of both seizures and pain. 6 State-and use-dependent characteristics, and subtype selectivity of voltage-gated channels can be measured in a straightforward manner using patch clamp methods. Automated, high-throughput platforms are preferred in screening and profiling studies, but until recently, automated patch clamp instruments lacked the required levels of throughput and flexibility. Systems such as IonWorksÔ Barracuda (IWB) that operate in a 384-well format can evaluate small chemical libraries in the range of 20,000-100,000 compounds. In the present study, we show that state dependence and subtype selectivity can be readily assessed in IWB assays in recombinant cell lines that stably express L-, N-, P/Q, or T-type calcium channels. supplemented with 10% fetal bovine serum, 100 U/mL of penicillin G sodium, 100 mg/mL of streptomycin sulfate, and the appropriate selection antibiotics. HEK293 cells were maintained in the Dulbecco's modified Eagle's medium/nutrient mixture F-12 (DMEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL of penicillin G sodium, 100 mg/ mL of streptomycin sulfate, and 500 mg/mL of G418 as the selection antibiotic. For experiments, the cells were passed in a medium lacking selection antibiotics 2-4 days. Expression was induced with tetracycline 16-14 h before recording. Verapamil at 3 mM was included in the induction medium to avoid Ca 2 + overload toxicity. Cell density was *50%-70% confluent at the time of harvest; two 150-mm plates (*1.2·10 7 cells) were used per population patch clamp (PPC) experiment.
MATERIALS AND METHODS

Cell Lines
Cells were harvested by washing twice with 15-20 mL of Hank's Balanced Salt Solution (HBSS) and treatment with 5 mL of AccutaseÔ (Innovative Cell Technologies, San Diego, CA) solution for 20 (CHO cells) or 60 (HEK293 cells) minutes. Cells were resuspended in a 50-mL conical tube with addition of 10 mL of HBSS and triturated with a serological pipette to resuspend the cells and break up cell clusters. Cells were pelleted at 500 g for 2.5 min, the supernatant was removed, and the cell pellet was resuspended in 10 mL of HBSS. The cell suspension was centrifuged again at 500 g for 2.5 min and the supernatant removed. Finally, the cell pellet was resuspended in 5 mL of HEPES-buffered physiological saline (HB-PS).
Solutions and Electrophysiological Procedures
Chemicals used in a solution preparation were purchased from Sigma-Aldrich (St. Louis, MO) and were of ACS reagent grade purity or higher. Stock solutions of test articles were prepared in dimethyl sulfoxide (DMSO) and stored frozen. Each test article formulation was sonicated (Model 2510/5510; Branson Ultrasonics, Danbury, CT) at ambient room temperature for 20 min to facilitate dissolution. Test article concentrations were prepared fresh daily by diluting stock solutions into extracellular solutions (HB-PS buffer). The solution composition was 137 mM NaCl, 4 mM KCl, 7 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, pH adjusted to 7.4 with NaOH. All test and control solutions contained 0.3% DMSO and 0.05% F-127. The test article formulations were prepared in 384-well compound plates using an automated liquid handling system (Cyclone, Caliper). The internal HEPES-buffered solution consisted of 90 mM CsF, 50 mM CsCl, 2 mM MgCl 2 , 0.5 mM EGTA, and 10 mM HEPES, pH 7.2 adjusted with CsOH. A stock solution of amphotericin B was prepared in DMSO (30 mg/mL) and added to the solution at a final concentration of 100 mg/mL. An extracellular buffer was loaded into the PPC plate wells (11 mL/well) and a cell suspension was added into the wells (9 mL/well). After establishment of a whole-cell configuration (a 10-min perforation), membrane currents were recorded by on-board patch clamp amplifiers in IWB. The data acquisition frequency was 5 kHz. Inward peak current amplitudes were measured. Under these conditions, each assay was completed in 45 min, and 5-10 experiments could be conducted each day.
Data Analysis
Initial data acquisition and analyses were performed using the IWB system operation software (version 2.0.2; Molecular Devices Corporation, Union City, CA). Data were corrected for leak current. The decrease in current amplitude after test article application was used to calculate the percent block relative to control. Results for each test article concentration (n = 3-4) were averaged, mean and standard deviation values were calculated and used to generate dose-response curves in XLfit add-in for Excel 2003 (Microsoft, Redmond, WA).
Drug effects were calculated as follows:
where I Baseline and I TA were the current amplitudes measured at baseline (before addition of a test article) and in the presence of a test article (or vehicle control), respectively.
If not specified, the data were corrected for run-down using the following equation:
where %VC and %PC were the mean values of the current inhibition with the vehicle and positive controls, respectively; inhibition by saturating concentrations of nifedipine (Ca v 1.2) or mibefradil (Ca v 2.1, Ca v 2.2, Ca v 3.2) was used as %PC value.
The concentration-response data for inhibitors were fit to an equation of the following form: 
Acceptance Criteria
Individual well data were filtered according to the criteria listed in Table 1 and the experiments were accepted based on the criteria listed in Table 2 .
The Z 0 factor and signal window (SW) in each experiment were calculated as follows: 
(iv).
Currents were elicited by applying test pulses from -80 to + 60 mV in 10 mV increments; the holding potential of -80 mV for Ca v 1.2 and -90 mV for other channels. In case of Ca v 3.2, a 500-ms conditioning voltage prepulse to -120 mV preceded each test pulse. The averaged current-voltage relationship is shown in (B) (mean -SE; n = 16). Superimposition of steady-state inactivation curves of Ca v channels is illustrated in (C). The currents were elicited by 400 ms test pulses, after 1-s, the conditioning prepulses (CPs) ranged from -120 to 50 mV (10 mV increments); the test pulse potentials were 10, 10, 30, and -30 mV for Ca v 1.2, Ca v 2.1, Ca v 2.2, and Ca v 3.2 channels, respectively.
where MeanVC and SDVC are the mean and standard deviation values for a vehicle control, and MeanPC and SDPC are the mean and standard deviation values for a positive control.
RESULTS
We developed cell lines that express recombinant voltage-gated Ca Figure 1A illustrates representative families of current traces for each channel recorded in IWB. Currents were evoked by voltage pulses that span the range from -80 to + 60 mV in 10 mV increments. The current-voltage relationships (Fig. 1B) show the expected separation of voltage ranges between the high-and low-voltage-activated channels. Thus, hCa v 1.2, hCa v 2.2, and hCa v 2.1 show peak responses at positive membrane potentials, whereas hCa v 3.2 peaks at about -30 mV. All four channel subtypes display voltage-dependent inactivation during prolonged depolarization (Fig. 1A) , as indicated by the return to baseline current. The voltage dependence of inactivation is plotted in Figure 1C . The channel subtypes also are distinguished on the basis of their pharmacological properties. The pore-forming a 1 subunits confer selective sensitivity to most of the known activators and inhibitors (with the exception of gabapentin and pregabalin that bind the auxiliary a 2 d subunit). In particular, Ca v 1.2 and other L-type channels are sensitive to dihydropyridine activators (e.g., BAY K8644) and inhibitors (e.g., nifedipine). Other high-voltage-activated and all low-voltage-activated Ca 2 + channels have low sensitivity to dihydropyridines. To evaluate the pharmacological responses of Ca v channels in the IWB platform, we tested a set of well-characterized reference inhibitors (diltiazem, nifedipine, verapamil, mibefradil, and pimozide) for use-and/or voltage-dependent inhibition. The assays were optimized by testing several different voltage protocols to obtain the best balance between sensitivity and success rate. Examples of results obtained with two different voltage protocols are illustrated in Figure 3 . A simple two-test pulse protocol (Fig. 3A) inhibition compared with the two-test pulse protocol described above. IC 50 values for the preconditioning protocol were 1.89, 0.013, and 2.43 mM, respectively, for verapamil, nifedipine, and diltiazem.
As an extension of the two-pulse voltage protocol, we evaluated use-dependent block augmentation by using stimulus patterns composed of repetitive test pulses. Figure 4 illustrates an experiment in which Ca v 2.2 channels were stimulated by repetitive 400-ms test pulses to + 20 mV from a holding potential -90 mV at frequency 0.1 Hz (30 test pulse train); mibefradil was added 5 min before stimulation by the TP1. Dose-response curves for the first (TP1) and last (TP30) test pulses were generated. Inhibition with mibefradil obtained at TP30 was about seven times more potent compared with the inhibition registered at TP1; IC 50 values were 4.8 and 32.7 mM, respectively.
To utilize the highthroughput capabilities and increased stimulus flexibility in the IWB system, and to obtain more accurate prediction of both use-and voltage-dependent effects, we validated a multiple-mode voltage protocol that could be used with Figure 5 and parameters specific for each Ca v channel are provided in Table 3 . IC 50 values for reference compounds are presented in Table 4 . The stimulus pattern consists of a combination of the two-pulse and use-dependent repetitive pulse patterns. As shown in the Ca v 2.2 example (Fig. 5) , the first test pulse (TP1) consists of a brief depolarizing stimulus ( + 30 mV amplitude, 400 ms duration) preceded by a long, depolarizing conditioning pulse (-50 mV amplitude, 1 s duration) that would be expected to cause partial inactivation. TP1 is applied to both pre (baseline)-and postcompound application to assess the inactivation-sensitive component of block. The second test pulse (TP2) consists of the same depolarizing stimulus as TP1, preceded by a hyperpolarizing conditioning potential (-100 mV amplitude, 2-s duration). At baseline, TP2 evaluates maximum activation of channels from their resting state. After test compound application, TP2 can be used as a measure of tonic block of resting channels. An additional use-dependent block arising from repetitive activation of the channels is evaluated by TP3 to TP32, consisting of a train of brief depolarizing pulses ( + 30 mV amplitude, 400 ms duration, from -90 mV holding potential, delivered repetitively at 10-s intervals). It is noteworthy that TP3, the initial pulse in the train, is preceded by a 30-s conditioning interval at the holding potential (-90 mV) and provides an alternative index of tonic block of the resting state. Block augmentation (postcompound addition) beyond the level attained in the resting state (i.e., use-dependent block) is measured by comparing peak current amplitudes, TP3 versus TP32, normalized to the effects of repetitive stimulation in channels exposed to vehicle alone. Ca v 2.2 current traces elicited by the multiple mode assay (Fig. 5B) illustrate the blocking characteristics of mibefradil and verapamil. Mibefradil shows use-dependent, but not inactivation-dependent block augmentation. By contrast, verapamil shows both inactivation-and use-dependent block amounting to an approximately threefold increase in block compared with tonic levels at -90 mV preconditioning, as illustrated in Figure 6 that plots the concentration-response curves for each Ca v channel. Table  4 presents IC 50 values for voltage-and use-dependent block in the multiple mode assay. In these experiments, calculation of the Z 0 statistic for TP1, using reference antagonists ( Table 5 ) gave values exceeding 0.5 in each case, indicative of a robust assay. 10 
DISCUSSION
Voltage-gated calcium (Ca v ) channels activate as a function of membrane potential such that the probability of opening increases with membrane depolarization, but with prolonged depolarization the channels transit to a closed, inactivated state that can be both voltage and calcium dependent. Thus, changes in membrane potential populate different conformational states (closed, open, or inactivated) of the channel. It is well known that a drug binding to Ca v channels often shows state dependence such that the affinity of antagonist binding changes depending upon the channel conformation.
11
The goal of this study was to develop patch clamp assays of recombinant calcium channels that take full advantage of the flexibility and throughput capabilities of the recently released IWB automated patch clamp system. We were able to optimize assays for state-and usedependent blocks in four different human Ca v subtypes using a standardized pulse protocol. It should be recognized that the standard protocol developed here provides a useful tool for evaluating Ca v subtype selectivity and for identifying dynamic characteristics of compounds, but may not be ideal for screening every class of compounds. For instance, compounds that require long exposure time or show a tendency to adsorb to the apparatus may require lengthened preincubation times and multiple applications at the expense of decreasing the number of data points that can be acquired per day. Therefore, in screening programs that require a high volume of output and rapid turnaround, pilot studies that allow further optimization for the classes of compounds to be tested and for the desired characteristics of the actives may be necessary. Another major consideration in designing an appropriate protocol would be data reduction and analysis. Our standard protocol yields Table 4 . These results highlight the differences between the channel subtypes. For instance, the dihydropyridine compounds nifedipine and antagonist, and BAY K8644, a potentiator, were effective in these roles only in Ca v 1.2. Other compounds showed less subtype selectivity. Thus, mibefradil, a use-dependent blocker that was originally described as a selective T-type channel antagonist and later shown to be a mixed T/L-blocker, 12 Figure 5 ; specific voltage parameters for each Ca v channel are presented in Table 3 . For each test compound and Ca v channel target, three curves are superimposed: TP1 (circles)-the curve generated at the test pulse after the CP, TP3 (triangles)-the curve generated at the first test pulse from the holding potential, and TP32 (inverted triangles)-the curve generated at the last test pulse from the holding potential. IC 50 values for the curves are presented in Table 4 . Table 4 ) was approximately sixfold higher than that reported by Martin et al. 13 The use dependence of mibefradil may account for this discrepancy. As is typical in manual patch clamp, the onset of block was evaluated by repetitive stimulation at 0.1 Hz until a steady-state effect was observed, 13 allowing cumulative usedependent block, whereas in the IWB assay, stimulation was performed only once after exposure to the test compound for a fixed interval. Nonetheless, in IWB, by stimulating with a brief high-frequency train, we were able to achieve an IC 50 value of 2.0 ( 
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